1. It is time to reconsider leukoreduction of whole blood for use in patients with life‐threatening hemorrhage.
- Author
-
Yazer, Mark H., Beckett, Andrew, Bloch, Evan M., Cap, Andrew P., Cohn, Claudia S., Gurney, Jennifer, Hermelin, Daniela, and Spinella, Philip C.
- Subjects
- *
HTLV , *RED blood cell transfusion , *BLOOD platelet aggregation , *LEUCOCYTES , *ERYTHROCYTES , *BLOOD transfusion reaction , *GLUCOSE-6-phosphate dehydrogenase deficiency - Abstract
The article delves into the reconsideration of leukoreduction of whole blood for patients facing life-threatening hemorrhage, particularly in trauma centers and military blood programs. It examines the benefits and limitations of leukoreduction in reducing febrile reactions, CMV transmission, and HLA alloimmunization, as well as the operational challenges and benefits. The text also compares the use of leukoreduced (LR) and non-LR whole blood for transfusion purposes, highlighting cost implications, shelf life differences, and the need for further clinical trials to determine effects on patient outcomes. The article underscores the importance of carefully weighing the potential benefits and risks of using LR versus non-LR whole blood in clinical decision-making for patients with major bleeding. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF